RALEIGH, N.C.--(BUSINESS WIRE)--Erimos Pharmaceuticals, a growing biopharmaceutical company focused on the discovery and development of new therapeutics to treat cancer and other serious diseases, today announced that patient dosing has commenced in a weekly dose Phase I study for its lead product candidate, terameprocol (EM-1421), for the treatment of solid tumors that are unresponsive to conventional therapy.
